পৃষ্ঠা 1 থেকে 20 ফলাফল
TECHNICAL FIELD
The invention relates to implantable medical devices and, more particularly, leads for electrical stimulators.
BACKGROUND
Electrical stimulation is an effective therapy for a variety of conditions and diseases that adversely affect patient health. For example, electrical stimulation
TECHNICAL FIELD
The invention relates to implantable medical devices and, more particularly, implantable electrical stimulators.
BACKGROUND
Electrical stimulation is an effective therapy for a variety of conditions and diseases that adversely affect patient health. For example, electrical
The invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as
The invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as
The invention relates to 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such as atherosclerosis,
FIELD OF THE INVENTION
The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention
FIELD OF THE INVENTION
The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention
FIELD OF THE INVENTION
The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention
FIELD OF THE INVENTION
The present invention relates to novel compounds, to processes for preparing them and to their use in treating medical disorders.
BACKGROUND OF THE INVENTION
1-[4-(5-Cyanoindol-3-yl)butyl]-4-(2-carbamoyl -benzofuran-5-yl)-piperazine, its physiologically acceptable salts
FIELD OF THE INVENTION
The present invention relates to novel compounds, to processes for preparing them and to their use in treating medical disorders.
BACKGROUND OF THE INVENTION
1-[4-(5-Cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine- , its physiologically acceptable salts
FIELD OF THE INVENTION
The present invention relates to novel compounds, to processes for preparing them and to their use in treating medical disorders.
BACKGROUND OF THE INVENTION
1-[4-(5-Cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine- , its physiologically acceptable salts
The present invention relates to compounds that are inhibitors of cysteine proteinases, pharmaceutical compositions containing said compounds, and their use in therapy. More specifically, the invention relates to compounds that are inhibitors of cathepsin S, a cysteine proteinase of the CA clan.
BACKGROUND TO THE INVENTION
Proteinases form a substantial group of biological molecules which to date constitute approximately 2% of all the gene products identified following analysis of several completed genome sequencing programmes. Proteinases have evolved to participate in an enormous range of
The present invention relates to compounds that are inhibitors of cysteine proteinases, pharmaceutical compositions containing said compounds, and their use in therapy. More specifically, the invention relates to compounds that are inhibitors of cathepsin S, a cysteine proteinase of the CA clan.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment